Altogether, our data illustrate a circSCAP/SF3A3/p53 signaling axis involved in the progression of NSCLC and identify circSCAP as a promising target for prognosis prediction and targeting therapy. Here, SF3A3 is linked to non-small cell lung carcinoma.